CyDex’ aqueous formulation capabilities will be developed with Aradigm’s inhalation delivery system.
Aradigm and CyDex are collaborating to combine products for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).
“Putting together Cydex’ aqueous formulation capabilities with Aradigm’s palm-size AERx Essence inhalation delivery system has the potential to generate a family of attractive novel therapies for asthma and COPD patients,” John Siebert, CEO of CyDex said.
Under the two-year agreement, Aradigm will bear 60% of the costs of development, and CyDex will be responsible for the rest. Third-party licensing and sales revenues will be shared in the same ratio.
The companies will develop and commercialize products containing inhaled corticosteroids, anticholinergics, and beta-2 agonists.